TITLE:
Study Evaluating the Safety and Efficacy of Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia

CONDITION:
Acute Myeloid Leukemia

INTERVENTION:
Gemtuzumab Ozogamicin

SUMMARY:

      The primary objectives are a) to establish the maximum tolerated dose (MTD) of gemtuzumab
      ozogamicin in combination with cytarabine and daunorubicin, and b) to assess the safety of
      gemtuzumab ozogamicin when given concurrently with cytarabine and daunorubicin.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to 59 Years
Criteria:

        Inclusion Criteria:

          -  All adult patients with relapsed or refractory AML, as well as younger de novo AML
             patients are eligible for the study

          -  Relapsed, refractory, and de novo AML patients are allowed in Phase I of this study

          -  Phase II will only allow enrollment of younger de novo AML

        Exclusion Criteria:

          -  AML following an antecedent hematologic disorder (myelodysplasia or
             myeloproliferation) of greater than 2 months duration

          -  De novo patients with M3 AML

          -  AML secondary to exposure to chemotherapy or radiation
      
